Skip to content

A medical records based study for comparative analysis on the treatment of children's recurrent respiratory tract infection based on famous and old Chinese Medicine

Research on Inheritance and Innovation of Experience (Integration of Tao and Shu) of Illustrious Senior Traditional Chinese Medicine Practitioners by adopting Multiple Research Methods

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005128
Enrollment
Unknown
Registered
2021-08-03
Start date
2019-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent respiratory tract infection in children

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria of Western medicine for children with recurrent respiratory tract infection; (2) the age was 1-14 years old; (3) the course of disease was at least 1 year, and the patient was in the non acute infection stage, and at least 1 week after the recovery of the acute infection stage; (4) the informed consent process met the requirements, and the legal representative or the children signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Children with severe primary respiratory tract infections such as primary immunodeficiency, acquired immunodeficiency syndrome (AIDS), congenital respiratory tract malformation, congenital heart disease, congenital ciliated immobility syndrome, gastroesophageal reflux disease (GERD) should be excluded; (2) Those who have used immunosuppressants or immunopotentiators in the past year, as well as those who have taken other drugs for the treatment of recurrent respiratory tract infection, should evaluate the impact of these drugs on the incidence and condition of respiratory tract infection, and generally should be excluded; (3) It is accompanied by serious primary diseases such as heart, liver, kidney, digestive and hematopoietic system; (4) According to the judgment of the researchers, other diseases or conditions that reduce the possibility of enrollment or complicate the enrollment, such as unstable living environment and inconvenient transportation, are likely to cause loss of follow-up; (5) Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The methods of syndrome differentiation and treatment, diagnosis and treatment techniques, medication characteristics, core prescriptions and so on of different famous old Chinese medicine in the treatment of the disease;

Countries

China

Contacts

Public ContactXiaohong Gu
guxiaohong1962@163.com+86 13910783120

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026